Navigation Links
Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
Date:3/11/2008

Genome scale RNAi analysis affordable and accessible to all researchers

HUNTSVILLE, Ala., March 11 /PRNewswire/ -- Open Biosystems, Inc. announced today that Harvard Medical School and the University of North Carolina have joined the Open Access(TM) RNAi Program. Each University purchased access to whole genome human and mouse lentiviral shRNA libraries developed by The RNAi Consortium and distributed by Open Biosystems.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070423/CLM143LOGO )

Tal Kafri M.D. Ph.D., Associate Professor in the Department of Microbiology and Immunology at the Gene Therapy Center, said, "Open Biosystems' Open Access Program empowers all researchers at the University of North Carolina with the ultimate promise of RNAi by offering unrestricted access to genome scale RNAi resources. From knockdown of single genes to pathway and whole genome RNAi screening with lentiviral shRNA, this program will definitely accelerate the pace of discovery at UNC."

"They are a welcome addition to the collaborative network of investigators worldwide implementing the latest advancements in shRNA technologies," said Troy Moore, Chief Technical Officer. "Participation in the Open Access Program enables investigators throughout these institutions to access their choice of Open Biosystems' unique portfolio of genome-wide RNAi resources."

Open Biosystems' portfolio of RNAi resources include shRNAmir lentiviral and retroviral libraries targeting the entire human and mouse genomes, The RNAi Consortium human and mouse lentiviral shRNA libraries and RNAi libraries targeting Drosophila, C. elegans and Arabidopsis thaliana. Participation in the Open Access RNAi program provides researchers the most complete and flexible access to their choice of these rapidly evolving RNAi technologies.

About Open Access RNAi

The Open Biosystems Open Access RNAi Program gives entire academic systems, including multiple campuses, access to the company's advanced RNAi libraries, priority technical support, and continued access to all extensions of existing libraries as well as library upgrades. In this manner, Open Biosystems supports academic research without imposing heavy financial burdens on individual labs. The program is customizable and can be tailored to fit the diverse needs of research institutions worldwide. Complete details can be found at http://www.openbiosystems.com/OpenAccessRNAi.

About Open Biosystems

Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit http://www.openbiosystems.com.


'/>"/>
SOURCE Open Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
2. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
3. Primera Biosystems Raises $21 Million in Series B Private Round
4. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
7. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio
9. Escalon(R) Announces FDA 510(K) Clearance for VascuView(TM) Visual Ultrasound System For Assisted Vascular Access
10. Access Pharmaceuticals Announces $2.7 Million New Equity
11. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):